Key statistics dashboard for Indaptus Therapeutics, Inc. (INDP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.
Stock Data
| Price | $3.21 |
| Market Cap | $364M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.46 |
| Price / Book | 32.78 |
| P/S | 0.00 |
| P/FCF | -23.94 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 19.48 |
| Quick Ratio | 19.48 |
| Cash Ratio | 12.27 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -18.57 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.10 |
| Cash per share | 0.10 |
| FCF per share | -0.13 |
| Tangible Book Value per share | 0.10 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Related companies: ATXI · AZTR · GTBP · LIPO · NKGN · PBM · PTIX
Explore sector: Healthcare · Biotechnology
More sections of INDP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks